Rochester, NY — Clerio Vision, Inc., a developer of next-generation vision correction platforms, today announced the successful closing of its financing round.

The round was led by Safar Partners, with participation from existing investors including Hegemon Capital. The influx of capital will be primarily dedicated to accelerating the clinical development of the company’s proprietary LIRIC technology.

"This funding represents a significant vote of confidence in our team and our technology," said Alex Zapesochny, CEO of Clerio Vision. "We are now well-positioned to complete our next set of multifocal contact lens studies and bring this transformative, non-invasive technology to patients worldwide."

Unlike traditional multifocal contact lenses, LIRIC uses a femtosecond laser to inscribe diffractive optics into the contact lens to provide improved visual acuity and quality across all distances.

Clerio Vision, Inc., a developer of next-generation vision correction products, today announced the publication of a pivotal new study co-authored by Len Zheleznyak, EVP of Vision Science at Clerio Vision.

The keynote, titled "Chromatic Aberration and Eye Growth," presented a novel framework for understanding how the eye focuses different wavelengths of light, known as Longitudinal Chromatic Aberration (LCA), and how correcting this aberration can fundamentally transform contact lens performance.

The "Stop" Sign for Myopia

Dr. Zheleznyak's presentation highlighted a critical link between LCA and the progression of myopia (nearsightedness). While traditional theories focus on refractive blur, research (Gawne, Schaeffel) suggests that the eye uses the separation of colors (chromatic cues) to determine its growth direction. By precisely correcting LCA, a contact lens can provide a distinct "stop" signal to the eye, potentially halting the axial elongation that defines myopia.

"For decades, we have treated LCA as a minor optical imperfection," said Dr. Zheleznyak. "Previous research indicates it is actually a primary driver of eye growth. By correcting LCA, we are not just sharpening the image; we are changing the biological instructions the eye receives."

Enhancing Visual Acuity for All Patients

Beyond pediatric applications, the keynote demonstrated that LCA correction offers significant benefits for the general adult population. Conventional single-vision contact lenses often leave residual chromatic blur, which limits the "crispness" of vision. Zheleznyak presented data (Roorda / UC Berkley and Nankivil / JnJ) showing that correcting LCA of the eye results in measurable improvements in visual acuity and contrast sensitivity, offering a "high-definition" visual experience unavailable in current standard soft lenses.

LIRIC: The Enabling Technology

Correcting LCA in a soft contact lens has historically been impossible with traditional molding or lathe-cutting manufacturing methods. Clerio Vision’s LIRIC technology is the only platform capable of writing the necessary diffractive-like optical patterns into a lens material to correct LCA.

"The optical profiles required to correct Longitudinal Chromatic Aberration are incredibly complex," said Alex Zapesochny, CEO of Clerio Vision. "You cannot simply mold them. You need to write them directly into the material with extreme precision. LIRIC allows us to impart these advanced optical corrections into standard contact lenses, opening the door to a new generation of products that both correct vision better than ever before and actively manage eye health."

About Clerio Vision

Clerio Vision is developing a breakthrough laser technology platform to treat vision issues. The company’s proprietary LIRIC technology modifies the refractive index of existing lens materials, enabling the non-invasive correction of refractive errors and the creation of advanced optical designs for presbyopia, myopia, and higher-order aberration correction.

New intellectual property secures method for manipulating peripheral blur orientation, a key signal for regulating eye growth, paving the way for upcoming clinical trials.

ROCHESTER, NY – January 5, 2026 – Clerio Vision, Inc., a developer of next-generation laser-based vision correction platforms, today announced the issuance of U.S. Patent No. 12,443,053 B2, titled "Myopia Control Treatments". The patent, awarded to inventors Len Zheleznyak, PhD, and Gustavo Gandara-Montano, PhD, covers a breakthrough lens design capable of modifying the orientation of light spread in the peripheral retina.

This intellectual property milestone supports Clerio Vision's developing portfolio of myopia control interventions. The patented technology addresses a critical "Optical Signature" identified by Clerio researchers: the specific orientation of peripheral blur.

The "Shape" of Focus Matters

Traditional myopia treatments often focus on the amount of peripheral defocus (blur). However, Clerio Vision's research indicates that the orientation of that blur, known as Optical Anisotropy, may be a more potent signal for the eye.

"Our research suggests that the eye is sensitive to the shape of the focal point in the peripheral retina," said Len Zheleznyak, EVP of Vision Science at Clerio Vision and co-inventor of the technology. "We have found that 'anti-radial' blur is endemic to myopic eyes. Switching that blur orientation to radial may be protective against myopia progression, based on choroidal thickness studies. This patent covers optical designs needed to flip peripheral blur orientation from 'grow' to 'stop' using contact lenses".

LIRIC: Precision Where It Matters

Creating these highly specific, asymmetric optical patterns is challenging with conventional contact lens molding. Clerio Vision's proprietary LIRIC technology is uniquely capable of "writing" these complex optical anisotropy profiles directly into the lens material with micrometer-level precision. This allows for the creation of a "stop signal" that is customized to the eye's natural optics.

Next Steps: Clinical Validation

With this key patent secured, Clerio Vision is moving forward with the design of additional clinical trials to validate the efficacy of these novel optical profiles in pediatric populations. The company aims to demonstrate that manipulating the orientation of peripheral blur can significantly slow the progression of myopia in children.

"Securing this patent is a pivotal step in our roadmap," said Alex Zapesochny, CEO of Clerio Vision. "It protects the fundamental mechanism of action behind our next-generation myopia control designs and allows us to proceed confidently into the clinical trial phase. We are excited to translate this scientific discovery into a therapeutic reality for millions of myopic children."

About Clerio Vision

Clerio Vision is developing a breakthrough laser technology platform to treat vision issues. The company's proprietary LIRIC technology modifies the refractive index of existing lens materials, enabling the non-invasive correction of refractive errors and the creation of advanced optical designs for presbyopia, myopia, and higher-order aberration correction.

New research presented in Hangzhou identifies peripheral retinal defocus as a key driver of eye growth, positioning LIRIC technology as a unique solution for halting myopia progression.

Clerio Vision, Inc., a developer of next-generation laser-based vision correction platforms, today announced that its leadership team presented groundbreaking new findings at the New Technology Symposium on Retinal Peripheral Vision held this month in Hangzhou, China.

Alex Zapesochny, CEO, and Len Zheleznyak, PhD, EVP of Vision Science, shared data from their presentation titled "The Role of Optical Cues in Myopia," which details how specific light signals in the peripheral retina act as "traffic lights" for eye growth, signaling the eye to either "STOP" or "GROW".

With global myopia prevalence projected to reach 50% of the world's population by 2050, identifying the root biological drivers of the condition has become urgent. The data presented by Clerio Vision highlights that the eye is the only organ whose growth is directly guided by photons, specifically through optical cues such as light levels, spectrum, and optical aberrations found in the peripheral visual field.

Decoding the "Optical Code" of Eye Growth

The presentation revealed that the interaction between the eye's natural Longitudinal Chromatic Aberration (LCA) and peripheral wavefront aberrations creates a distinct "optical signature" that the retina uses to determine whether to elongate.

"Our research demonstrates that the orientation and color of blur in the peripheral retina differ fundamentally between myopic and emmetropic (normal) eyes," said Dr. Zheleznyak. "We found that specific optical cues, such as the orientation of peripheral astigmatism, effectively tell the eye whether an image is focused in front of or behind the retina. By deciphering these cues, we can understand why near-work environments, which often present anti-radial blur patterns, may trigger excessive eye growth".

LIRIC: Writing the Cure into the Lens

While traditional contact lens manufacturing is limited in its ability to manipulate these complex peripheral signals, Clerio's proprietary LIRIC technology offers a novel solution. LIRIC can "write" precise, diffractive-like optical patterns directly into the contact lens material to mimic the protective optical cues found in emmetropic eyes, without degrading central vision quality.

"China is at the forefront of the myopia epidemic, with prevalence rates in urban centers like Hong Kong and Singapore having skyrocketed over the last few decades," said Alex Zapesochny, CEO of Clerio Vision. "It was an honor to share our findings in Hangzhou. We believe LIRIC is uniquely suited to address this challenge because it allows us to imprint the exact optical 'stop signal' the eye needs directly into a contact lens, offering a potential functional cure for myopia progression."

About Clerio Vision

Clerio Vision is developing a breakthrough laser technology platform to treat vision issues. The company's proprietary LIRIC technology modifies the refractive index of existing lens materials, enabling the non-invasive correction of refractive errors and the creation of advanced optical designs for presbyopia and myopia.

Clerio Vision, Inc., a developer of next-generation laser-based vision correction platforms, today announced that Len Zheleznyak, PhD, Executive Vice President of Vision Science, delivered a keynote lecture at the prestigious Visual and Physiological Optics (VPO) Conference held this week in Wroclaw, Poland.

The keynote, titled "Chromatic Aberration and Eye Growth," presented a novel framework for understanding how the eye focuses different wavelengths of light, known as Longitudinal Chromatic Aberration (LCA), and how correcting this aberration can fundamentally transform contact lens performance.

The "Stop" Sign for Myopia

Dr. Zheleznyak's presentation highlighted a critical link between LCA and the progression of myopia (nearsightedness). While traditional theories focus on refractive blur, research (Gawne, Schaeffel) suggests that the eye uses the separation of colors (chromatic cues) to determine its growth direction. By precisely correcting LCA, a contact lens can provide a distinct "stop" signal to the eye, potentially halting the axial elongation that defines myopia.

"For decades, we have treated LCA as a minor optical imperfection," said Dr. Zheleznyak. "Our research indicates it is actually a primary driver of eye growth. By correcting LCA, we are not just sharpening the image; we are changing the biological instructions the eye receives."

Enhancing Visual Acuity for All Patients

Beyond pediatric applications, the keynote demonstrated that LCA correction offers significant benefits for the general adult population. Conventional single-vision contact lenses often leave residual chromatic blur, which limits the "crispness" of vision. Zheleznyak presented data (Roorda, Nankivil) showing that correcting LCA of the eye results in measurable improvements in visual acuity and contrast sensitivity, offering a "high-definition" visual experience unavailable in current standard soft lenses.

LIRIC: The Enabling Technology

Correcting LCA in a soft contact lens has historically been impossible with traditional molding or lathe-cutting manufacturing methods. Clerio Vision’s LIRIC technology is the only platform capable of writing the necessary diffractive-like optical patterns into a lens material to correct LCA.

"The optical profiles required to correct Longitudinal Chromatic Aberration are incredibly complex," said Alex Zapesochny, CEO of Clerio Vision. "You cannot simply mold them. You need to write them directly into the material with extreme precision. LIRIC allows us to impart these advanced optical corrections into standard contact lenses, opening the door to a new generation of products that both correct vision better than ever before and actively manage eye health."

About Clerio Vision

Clerio Vision is developing a breakthrough laser technology platform to treat vision issues. The company’s proprietary LIRIC technology modifies the refractive index of existing lens materials, enabling the non-invasive correction of refractive errors and the creation of advanced optical designs for presbyopia, myopia, and higher-order aberration correction.